De ce acțiunile SLS cresc înainte de deschidere: SELLAS Life Sciences repune în joc numărătoarea inversă pentru studiul REGAL Faza 3
SELLAS Life Sciences rose 3.4% premarket Monday to $4.29 after closing Friday at $4.15, up 2.7%. Trading volume hit 5.9 million as investors watched for updates from the phase 3 AML trial, with 72 of 80 required events reached. The company reported $71.8 million in cash at year-end and a short interest of 24.4%.